380 related articles for article (PubMed ID: 26805380)
1. Targeting mTOR for the treatment of B cell malignancies.
Lee JS; Vo TT; Fruman DA
Br J Clin Pharmacol; 2016 Nov; 82(5):1213-1228. PubMed ID: 26805380
[TBL] [Abstract][Full Text] [Related]
2. Drug discovery targeting the mTOR pathway.
Martelli AM; Buontempo F; McCubrey JA
Clin Sci (Lond); 2018 Mar; 132(5):543-568. PubMed ID: 29523752
[TBL] [Abstract][Full Text] [Related]
3. Catalytic mammalian target of rapamycin inhibitors as antineoplastic agents.
Mohindra NA; Platanias LC
Leuk Lymphoma; 2015; 56(9):2518-23. PubMed ID: 25747970
[TBL] [Abstract][Full Text] [Related]
4. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
Grzybowska-Izydorczyk O; Smolewski P
Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
[TBL] [Abstract][Full Text] [Related]
5. m-TOR inhibitors and their potential role in haematological malignancies.
Calimeri T; Ferreri AJM
Br J Haematol; 2017 Jun; 177(5):684-702. PubMed ID: 28146265
[TBL] [Abstract][Full Text] [Related]
6. Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies.
Khokhar NZ; Altman JK; Platanias LC
Curr Opin Oncol; 2011 Nov; 23(6):578-86. PubMed ID: 21892085
[TBL] [Abstract][Full Text] [Related]
7. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors.
Zhang YJ; Duan Y; Zheng XF
Drug Discov Today; 2011 Apr; 16(7-8):325-31. PubMed ID: 21333749
[TBL] [Abstract][Full Text] [Related]
8. Utility of mTOR inhibition in hematologic malignancies.
Younes A; Samad N
Oncologist; 2011; 16(6):730-41. PubMed ID: 21632450
[TBL] [Abstract][Full Text] [Related]
9. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies.
Teachey DT; Grupp SA; Brown VI
Br J Haematol; 2009 Jun; 145(5):569-80. PubMed ID: 19344392
[TBL] [Abstract][Full Text] [Related]
10. Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.
Sankhala K; Giles FJ
Expert Rev Hematol; 2009 Aug; 2(4):399-414. PubMed ID: 21082945
[TBL] [Abstract][Full Text] [Related]
11. mTOR kinase inhibitors as potential cancer therapeutic drugs.
Sun SY
Cancer Lett; 2013 Oct; 340(1):1-8. PubMed ID: 23792225
[TBL] [Abstract][Full Text] [Related]
12. Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update.
Simioni C; Martelli AM; Zauli G; Vitale M; McCubrey JA; Capitani S; Neri LM
J Cell Physiol; 2018 Oct; 233(10):6440-6454. PubMed ID: 29667769
[TBL] [Abstract][Full Text] [Related]
13. New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma.
Agulnik M
Cancer; 2012 Mar; 118(6):1486-97. PubMed ID: 21837674
[TBL] [Abstract][Full Text] [Related]
14. Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055.
Marshall G; Howard Z; Dry J; Fenton S; Heathcote D; Gray N; Keen H; Logie A; Holt S; Smith P; Guichard SM
Biochem Soc Trans; 2011 Apr; 39(2):456-9. PubMed ID: 21428919
[TBL] [Abstract][Full Text] [Related]
15. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition.
Limon JJ; So L; Jellbauer S; Chiu H; Corado J; Sykes SM; Raffatellu M; Fruman DA
Proc Natl Acad Sci U S A; 2014 Nov; 111(47):E5076-85. PubMed ID: 25385646
[TBL] [Abstract][Full Text] [Related]
16. Mammalian target of rapamycin as a target in hematological malignancies.
Kelly KR; Rowe JH; Padmanabhan S; Nawrocki ST; Carew JS
Target Oncol; 2011 Mar; 6(1):53-61. PubMed ID: 21499765
[TBL] [Abstract][Full Text] [Related]
17. PI3K and mTOR signaling pathways in cancer: new data on targeted therapies.
Willems L; Tamburini J; Chapuis N; Lacombe C; Mayeux P; Bouscary D
Curr Oncol Rep; 2012 Apr; 14(2):129-38. PubMed ID: 22350330
[TBL] [Abstract][Full Text] [Related]
18. Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors.
Delbaldo C; Albert S; Dreyer C; Sablin MP; Serova M; Raymond E; Faivre S
Target Oncol; 2011 Jun; 6(2):119-24. PubMed ID: 21533544
[TBL] [Abstract][Full Text] [Related]
19. Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies.
Chapuis N; Tamburini J; Green AS; Willems L; Bardet V; Park S; Lacombe C; Mayeux P; Bouscary D
Leukemia; 2010 Oct; 24(10):1686-99. PubMed ID: 20703258
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside.
Vincenzi B; Napolitano A; D'Onofrio L; Frezza AM; Silletta M; Venditti O; Santini D; Tonini G
Expert Opin Investig Drugs; 2011 Dec; 20(12):1685-705. PubMed ID: 22010859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
